{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T16:17:30Z","timestamp":1789143450378,"version":"build-2803163510"},"reference-count":21,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T00:00:00Z","timestamp":1736208000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Restless Legs Syndrome (RLS), also known as Willis-Ekbom Disease (WED), is a sensorimotor disorder characterized by an uncontrollable urge to move the legs, typically accompanied by discomfort. Low iron levels, pregnancy, and age are some identified risk factors. RLS is treated using various pharmacological options, including dopamine agonists, benzodiazepines, anticonvulsants, opioids, and bupropion. Iron supplementation, particularly with intravenous Ferric carboxymaltose (FCM), has gained attention due to the role of iron deficiency in RLS pathophysiology. This meta-analysis evaluates the efficacy and safety of FCM in treating RLS symptoms.<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and methods<\/jats:title><jats:p>A systematic review and meta-analysis were conducted following the PRISMA guidelines, using databases such as PubMed, Google Scholar, and Cochrane. Studies involving intravenous FCM in patients diagnosed with RLS were included. Statistical analysis was performed using Review Manager 5.4.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Seven studies involving 539 participants were analyzed. FCM significantly reduced IRLS scores (WMD = \u22125.77; 95% CI = [\u22128.85, \u22122.70]; <jats:italic>p<\/jats:italic> = 0.0002) and improved VAS and SF-36 scores compared to placebo. However, FCM did not significantly improve RLS quality of life scores. Adverse events were more common in the FCM group, particularly nausea, but no significant differences were found for severe adverse events.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>In conclusion, intravenous ferric carboxymaltose significantly reduces Restless Legs Syndrome symptoms, especially in patients with confirmed iron deficiency. The treatment appears generally well-tolerated, with adverse effects being manageable. However, further long-term studies are needed to fully assess the safety profile and confirm sustained symptom improvement in a broader population.<\/jats:p><\/jats:sec><jats:sec><jats:title>Systematic review registration<\/jats:title><jats:p><jats:ext-link>https:\/\/www.crd.york.ac.uk\/prospero\/<\/jats:ext-link>, identifier: CRD42024585233.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fneur.2024.1503342","type":"journal-article","created":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T05:26:27Z","timestamp":1736227587000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Efficacy and safety of intravenous ferric carboxymaltose in the treatment of Restless Legs Syndrome: a systematic review and meta-analysis"],"prefix":"10.3389","volume":"15","author":[{"given":"Ayesha","family":"Khan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harsh","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuldeep Dalpat","family":"Rai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anzel","family":"Saeed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jawad","family":"Ishtiaq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Tanveer Alam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sakshi","family":"Chawla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Md Ariful","family":"Haque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,1,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"S401","DOI":"10.1002\/mds.21604","article-title":"Definition of restless legs syndrome, how to diagnose it, and how to differentiate it from RLS mimics","volume":"22","author":"Benes","year":"2007","journal-title":"Mov Disord."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1212\/01.WNL.0000163996.64461.A3","article-title":"Restless legs syndrome","volume":"64","author":"Hogl","year":"2005","journal-title":"Neurology."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1001\/archinte.165.11.1286","article-title":"Restless legs syndrome prevalence and impact","volume":"165","author":"Allen","year":"2005","journal-title":"Arch Intern Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.smrv.2011.05.002","article-title":"Epidemiology of restless legs syndrome: a synthesis of the literature","volume":"16","author":"Ohayon","year":"2012","journal-title":"Sleep Med Rev."},{"key":"B5","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1002\/mds.1102","article-title":"Restless legs syndrome in an Asian population: a study in Singapore","volume":"16","author":"Tan","year":"2001","journal-title":"Mov Disord."},{"key":"B6","first-page":"739","article-title":"Restless legs syndrome and sleep bruxism: prevalence and association among Canadians","volume":"17","author":"Lavigne","year":"1994","journal-title":"Sleep"},{"key":"B7","doi-asserted-by":"publisher","first-page":"2323","DOI":"10.1001\/archinte.163.19.2323","article-title":"Restless legs syndrome symptoms in primary care","volume":"163","author":"Nichols","year":"2003","journal-title":"Arch Intern Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1002\/mds.22806","article-title":"Restless legs syndrome in a population of northern Tanzania: a community-based study","volume":"25","author":"Winkler","year":"2010","journal-title":"Mov Disord."},{"key":"B9","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.sleep.2005.03.004","article-title":"Gender differences in the presentation of subjects with restless legs syndrome","volume":"7","author":"Bentley","year":"2006","journal-title":"Sleep Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1212\/WNL.10.9.868","article-title":"Restless legs syndrome","volume":"10","author":"Ekbom","year":"1960","journal-title":"Neurology."},{"key":"B11","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1111\/j.1365-2796.2009.02159.x","article-title":"Restless legs syndrome","volume":"266","author":"Ekbom","year":"2009","journal-title":"J Intern Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1001\/archinte.160.14.2137","article-title":"Epidemiology of restless legs symptoms in adults","volume":"160","author":"Phillips","year":"2000","journal-title":"Arch Intern Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.sleep.2004.03.006","article-title":"Impact, diagnosis and treatment of restless legs syndrome (RLS) in a primary care population: the REST (RLS epidemiology, symptoms, and treatment) primary care study","volume":"5","author":"Hening","year":"2004","journal-title":"Sleep Med."},{"key":"B14","doi-asserted-by":"publisher","first-page":"739","DOI":"10.2165\/00003495-200969060-00007","article-title":"Ferric carboxymaltose","volume":"69","author":"Lyseng-Williamson","year":"2009","journal-title":"Drugs."},{"key":"B15","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"2021","author":"Page","year":"2021","journal-title":"Br Med J"},{"key":"B16","doi-asserted-by":"publisher","first-page":"615","DOI":"10.31128\/AJGP-02-23-6722","article-title":"Restless legs syndrome","volume":"52","author":"Nanayakkara","year":"2023","journal-title":"Aust J Gen Pract."},{"key":"B17","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.neuroscience.2013.04.049","article-title":"Effects of IV iron isomaltoside-1000 treatment on regional brain iron status in an iron-deficient animal","volume":"246","author":"Unger","year":"2013","journal-title":"Neuroscience."},{"key":"B18","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.ejim.2019.02.009","article-title":"Iron supplementation for restless legs syndrome - a systematic review and meta-analysis","volume":"63","author":"Avni","year":"2019","journal-title":"Eur J Intern Med."},{"key":"B19","first-page":"15","article-title":"Self-report scales and procedures for assessing pain in adults","author":"Jensen","year":"2011","journal-title":"Handbook of Pain Assessment"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1037\/t06708-000","article-title":"The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection","author":"Ware Jr","year":"1992","journal-title":"Med Care."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.3390\/jcm11061673","article-title":"Does repeated dosing of intravenous ferric carboxymaltose alleviate symptoms of restless legs syndrome?","volume":"11","author":"Park","year":"2022","journal-title":"J Clin Med."}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2024.1503342\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T05:26:33Z","timestamp":1736227593000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2024.1503342\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,7]]},"references-count":21,"alternative-id":["10.3389\/fneur.2024.1503342"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2024.1503342","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,7]]},"article-number":"1503342"}}